We are live on
!
Find out more
AI
Allostery Investments Portfolio holdings
AUM
$7.85M
This Fund
S&P 500
This Quarter
Est. Return
-14.08%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.7M
AUM Growth
–
Cap. Flow
+$106M
Cap. Flow
% of AUM
110.83%
Top 10 Holdings %
Top 10 Hldgs %
69.94%
Holding
40
New
40
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Evolus
EOLS
|
+$6.06M |
| 2 |
ABVX
Abivax
ABVX
|
+$5.44M |
| 3 |
Zura Bio
ZURA
|
+$5.4M |
| 4 |
Apogee Therapeutics
APGE
|
+$5.1M |
| 5 |
KALV
KalVista Pharmaceuticals
KALV
|
+$4.96M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
| $15.8M | 16.46% |
+175,000
| New | +$17M |
|
2
PUT
Invesco QQQ Trust
QQQ
$438B
| $12.8M | 13.35% |
+25,000
| New | +$12.6M |
|
3
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$42.4B
| $8.73M | 9.12% |
+100,000
| New | +$9.2M |
|
|
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
| $4.77M | 4.98% |
+284,517
| New | +$4.71M |
|
|
5
Evolus
EOLS
$395M
| $4.76M | 4.97% |
+431,117
| New | +$6.06M |
|
|
6
Apogee Therapeutics
APGE
$10.1B
| $4.53M | 4.73% |
+100,000
| New | +$5.1M |
|
|
ABVX
7
Abivax
ABVX
$10.4B
| $4.33M | 4.52% |
+591,253
| New | +$5.44M |
|
|
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
| $4.06M | 4.24% |
+479,100
| New | +$4.96M |
|
|
9
Zura Bio
ZURA
$512M
| $3.79M | 3.96% |
+1,515,126
| New | +$5.4M |
|
10
Alkermes
ALKS
$8.09B
| $3.45M | 3.61% |
+120,000
| New | +$3.45M |
|
11
Cytokinetics
CYTK
$10.7B
| $3.06M | 3.19% |
+65,000
| New | +$3.38M |
|
|
ACLX
12
DELISTED
Arcellx
ACLX
| $2.68M | 2.8% |
+35,000
| New | +$3.02M |
|
|
APLS
13
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $2.55M | 2.67% |
+80,000
| New | +$2.41M |
|
14
Ionis Pharmaceuticals
IONS
$8.98B
| $2.27M | 2.37% |
+65,000
| New | +$2.43M |
|
15
CALL
TG Therapeutics
TGTX
$8.21B
| $2.26M | 2.36% |
+75,000
| New | +$2.15M |
|
|
JBIO
16
Jade Biosciences
JBIO
$1.18B
| $2.25M | 2.35% |
+24,305
| New | +$2.09M |
|
17
PUT
Novavax
NVAX
$1.21B
| $1.21M | 1.26% |
+150,000
| New | +$1.45M |
|
18
Xenon Pharmaceuticals
XENE
$6.12B
| $1.18M | 1.23% |
+30,000
| New | +$1.24M |
|
19
Context Therapeutics
CNTX
$54.5M
| $998K | 1.04% |
+950,166
| New | +$1.64M |
|
|
MRUS
20
DELISTED
Merus
MRUS
| $914K | 0.95% |
+21,735
| New | +$1.04M |
|
|
DFTX
21
Definium Therapeutics
DFTX
$5.61B
| $905K | 0.95% |
+130,000
| New | +$894K |
|
22
Rallybio
RLYB
$85.1M
| $771K | 0.81% |
+100,425
| New | +$841K |
|
23
Tarsus Pharmaceuticals
TARS
$2.53B
| $753K | 0.79% |
+13,600
| New | +$618K |
|
24
Insmed
INSM
$22.3B
| $690K | 0.72% |
+10,000
| New | +$720K |
|
25
CALL
AnaptysBio
ANAB
$1.55B
| $662K | 0.69% |
+50,000
| New | +$1.21M |
|
Similar funds
CP
CAWM
ADIM
PC
AVM
NP
BPWM
CSD
Allostery Investments's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Allostery Investments, which disclosed 40 positions worth $95.7M. Its ten largest holdings account for 70% of the portfolio.
Its largest position is Evolus: 431,117 shares worth $4.76M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets.
- Allostery Investments's largest Q4 2024 buy was Evolus: 431,117 shares worth $4.76M.
- Allostery Investments's ten largest holdings make up 70% of its $95.7M portfolio in Q4 2024.
- Allostery Investments disclosed 40 positions in Q4 2024, its first 13F filing on record.
Based on Allostery Investments's 13F filing for Q4 2024, filed 14 Feb 2025.